Antibiotic Eye Drops Recalled for Sterility Assurance Failure
Pharmacy Innovations is recalling Tobramycin Fortified 15mg/mL Ophthalmic Solution nationwide due to insanitary facility conditions that compromised sterility assurance. Consumers should discontinue use and contact their healthcare provider.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall of a sterile product where manufacturing quality failures compromised sterility assurance. While no confirmed contamination or reported illnesses are stated in the source, non-sterile eye solutions carry significant risk of infection. The score reflects the high-risk nature of the hazard despite the absence of reported adverse events.
Plain-English summary
Pharmacy Innovations is recalling Tobramycin Fortified 15mg/mL Ophthalmic Solution, a prescription antibiotic eye drop, nationwide. The product is identified by code t20221104@17 and was manufactured at the company's facility in Erie, Pennsylvania.
The FDA inspection revealed insanitary conditions at the manufacturing facility that compromised the assurance of product sterility. Non-sterile ophthalmic solutions pose a risk of infection when used in the eye.
Patients and consumers who have obtained this product should discontinue use immediately. Anyone who has used this product and experiences symptoms of eye infection—including redness, discharge, pain, or changes in vision—should contact their healthcare provider.
The recalled product
- Product
- TOBRAMYCIN FORTIFIED 15MG/ML OPH SOLUTION, Rx Only, Pharmacy Innovations, 2936 W 17th St., Erie, PA.
- Manufacturer
- Pharmacy Innovations
- Category
- Drug — Ophthalmic / Eye Drops
- Hazard
- sterility-failure
- infection-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- t20221104@17
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27